JP2016520320A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520320A5
JP2016520320A5 JP2016516173A JP2016516173A JP2016520320A5 JP 2016520320 A5 JP2016520320 A5 JP 2016520320A5 JP 2016516173 A JP2016516173 A JP 2016516173A JP 2016516173 A JP2016516173 A JP 2016516173A JP 2016520320 A5 JP2016520320 A5 JP 2016520320A5
Authority
JP
Japan
Prior art keywords
activity
cell
variant
seq
onui
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016516173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520320A (ja
JP6450371B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/061189 external-priority patent/WO2014191527A1/en
Publication of JP2016520320A publication Critical patent/JP2016520320A/ja
Publication of JP2016520320A5 publication Critical patent/JP2016520320A5/ja
Application granted granted Critical
Publication of JP6450371B2 publication Critical patent/JP6450371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016516173A 2013-05-31 2014-05-28 T細胞受容体α遺伝子を開裂するLAGLIDADGホーミングエンドヌクレアーゼおよびその用途 Active JP6450371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370303 2013-05-31
DKPA201370303 2013-05-31
PCT/EP2014/061189 WO2014191527A1 (en) 2013-05-31 2014-05-28 A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof

Publications (3)

Publication Number Publication Date
JP2016520320A JP2016520320A (ja) 2016-07-14
JP2016520320A5 true JP2016520320A5 (enExample) 2017-07-06
JP6450371B2 JP6450371B2 (ja) 2019-01-09

Family

ID=48628226

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516173A Active JP6450371B2 (ja) 2013-05-31 2014-05-28 T細胞受容体α遺伝子を開裂するLAGLIDADGホーミングエンドヌクレアーゼおよびその用途

Country Status (8)

Country Link
US (1) US10000746B2 (enExample)
EP (1) EP3004338B1 (enExample)
JP (1) JP6450371B2 (enExample)
AU (1) AU2014273091B2 (enExample)
CA (1) CA2913872C (enExample)
DK (1) DK3004338T3 (enExample)
ES (1) ES2716867T3 (enExample)
WO (1) WO2014191527A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111953C (en) * 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン,インコーポレイテッド CRISPR関連方法および支配gRNAのある組成物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
DK3359660T3 (en) 2015-10-05 2020-02-17 Prec Biosciences Inc Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
DK3359184T3 (da) * 2015-10-05 2020-06-15 Prec Biosciences Inc Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
IL259576B (en) 2015-12-04 2022-09-01 Novartis Ag grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
RU2018135819A (ru) * 2016-03-11 2020-04-13 Блубёрд Био, Инк. Иммунные эффекторные клетки с отредактированным геномом
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP4711465A2 (en) * 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018022619A1 (en) * 2016-07-25 2018-02-01 Bluebird Bio, Inc. Bcl11a homing endonuclease variants, compositions, and methods of use
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
EP3500696A4 (en) * 2016-08-16 2020-04-08 Bluebird Bio, Inc. VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE
MA46059A (fr) * 2016-08-23 2019-07-03 Bluebird Bio Inc Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
ES2952525T3 (es) 2016-09-08 2023-11-02 2Seventy Bio Inc Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
AU2017342273B2 (en) * 2016-10-11 2023-07-06 Regeneron Pharmaceuticals, Inc. TCRa homing endonuclease variants
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
EP3526334A4 (en) * 2016-10-17 2020-09-30 Bluebird Bio, Inc. TGFBETA R2 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018102795A2 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3054621A1 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11767512B2 (en) 2017-04-13 2023-09-26 Cellectis Sequence specific reagents targeting CCR5 in primary hematopoietic cells
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
KR102742817B1 (ko) 2017-05-25 2024-12-17 리제너론 파마슈티칼스 인코포레이티드 Cblb 엔도뉴클레아제 변이체, 조성물 및 사용 방법
CA3068465A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019070974A1 (en) * 2017-10-04 2019-04-11 Bluebird Bio, Inc. PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
WO2019073965A1 (ja) 2017-10-10 2019-04-18 国立大学法人広島大学 エフェクターT細胞(Teff)抗原受容体を用いた抗原特異的制御性T細胞(Treg)の作出技術
CN111479830A (zh) * 2017-10-10 2020-07-31 国立大学法人广岛大学 使用铂talen的t细胞受体的完全取代技术
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US20210002621A1 (en) * 2017-12-20 2021-01-07 Bluebird Bio, Inc. Ctla4 homing endonuclease variants, compositions, and methods of use
JP7355742B2 (ja) 2018-01-18 2023-10-03 フレッド ハッチンソン キャンサー センター 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること
US11786554B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
AU2019395334A1 (en) 2018-12-10 2021-06-24 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
KR20240122580A (ko) 2019-04-03 2024-08-12 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
CA3148179A1 (en) 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20220411479A1 (en) 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20260028412A1 (en) 2020-08-10 2026-01-29 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
US20240336904A1 (en) * 2020-12-21 2024-10-10 2Seventy Bio, Inc. Compositions and methods for site-directed mutagenesis
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
IL312721A (en) 2021-11-23 2024-07-01 Cellectis Sa New tale protein scaffolds with improved on-target/off-target activity ratios
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
AU2024206812A1 (en) 2023-01-05 2025-08-14 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
WO2026046724A1 (en) 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011156430A2 (en) * 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
CA3111953C (en) * 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
WO2013009525A1 (en) * 2011-07-08 2013-01-17 Cellectis S.A. Method for increasing the efficiency of double-strand break-induced mutagenssis
US20130210151A1 (en) * 2011-11-07 2013-08-15 University Of Western Ontario Endonuclease for genome editing

Similar Documents

Publication Publication Date Title
JP2016520320A5 (enExample)
JP2016520319A5 (enExample)
JP7827321B2 (ja) エピゲノム編集のための組成物および方法
KR102796744B1 (ko) 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
JP2025065213A (ja) 免疫療法のための改変ナチュラルキラー(nk)細胞
JP2017018125A5 (enExample)
JP2023002785A (ja) 変異cas9タンパク質
TW202028466A (zh) 編輯RNAs的方法以及組成物
WO2013186563A3 (en) Factor viii sequences
JP2020530437A5 (enExample)
JP2015533786A5 (enExample)
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2015503535A5 (enExample)
JP2021521855A (ja) ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
JP2017513472A5 (enExample)
US11072782B2 (en) Construct for epigenetic modification and its use in the silencing of genes
JP2013530689A5 (enExample)
US12297426B2 (en) DNA damage response signature guided rational design of CRISPR-based systems and therapies
US20240279629A1 (en) Crispr-transposon systems for dna modification
CA3191148A1 (en) Engineered immune cells with priming receptors
EA201070108A1 (ru) Cd44 сплайс-варианты в нейродегенеративных заболеваниях
AU2021369494A9 (en) Safe harbor loci
KR20250134148A (ko) Scn9a 또는 scn10a 유전자를 변형시키기 위한 유전자-편집 시스템 및 이의 방법 및 용도
EA050294B1 (ru) Безопасный локус